A Botanical Skin Care Regimen on Mild to Moderate Acne and the Microbiome

Sponsor
Integrative Skin Science and Research (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05271487
Collaborator
Codex Beauty Corporation (Other)
20
1
1
11.8
1.7

Study Details

Study Description

Brief Summary

The purpose of this study is to analyze changes in acne and changes in the gut and skin microbiome with the use of a multi-step botanical skin care regimen in those with mild to moderate acne.

Condition or Disease Intervention/Treatment Phase
  • Other: Multi-Step Botanical Skin Care Regimen
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Effects of a Botanical Skin Care Regimen on Mild to Moderate Acne and the Microbiome
Anticipated Study Start Date :
Mar 7, 2022
Anticipated Primary Completion Date :
Jul 1, 2022
Anticipated Study Completion Date :
Mar 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Multi-Step Botanical Skin Care Regimen

The patient will be provided with and instructed to use a cleanser, toner, oil control cream, exfoliating facial scrub, clay mask, acne spot treatment, and body scrub for the duration of the study.

Other: Multi-Step Botanical Skin Care Regimen
The intervention includes 7 different topical products: Cleanser Toner Oil Control Cream Exfoliating Facial Scrub Clay Mask Acne Spot Treatment Body Scrub

Outcome Measures

Primary Outcome Measures

  1. Total lesion count [8 weeks]

    Number of of inflammatory lesions, and open and closed comedones

Secondary Outcome Measures

  1. Inflammatory lesion count [4 weeks]

    Number of inflammatory lesions

  2. Inflammatory lesion count [8 weeks]

    Number of inflammatory lesions

  3. Non-inflammatory lesion count [4 weeks]

    Number of open and closed comedones

  4. Non-inflammatory lesion count [8 weeks]

    Number of open and closed comedones

  5. Investigator global assessment (IGA) of acne [4 weeks]

    Validated scale for global assessment of acne. Scale is 0 to 4 with 4 indicating greater severity of acne

  6. Investigator global assessment (IGA) of acne [8 weeks]

    Validated scale for global assessment of acne. Scale is 0 to 4 with 4 indicating greater severity of acne

  7. Sebum excretion [4 weeks]

    Measure of skin sebum via sebumeter

  8. Sebum excretion [8 weeks]

    Measure of skin sebum via sebumeter

  9. Gut microbiome assessment [4 weeks]

    Gut microbiome shift for short-chain fatty acid producing bacteria via stool sample

  10. Gut microbiome assessment [8 weeks]

    Gut microbiome shift for short-chain fatty acid producing bacteria via stool sample

  11. Skin microbiome diversity [4 weeks]

    Shift in Shannon diversity of the skin microbiome

  12. Skin microbiome diversity [8 weeks]

    Shift in Shannon diversity of the skin microbiome

  13. Positive and Negative Affect Schedule (PANAS-SF) [4 weeks]

    Survey assessing positive and negative mood states. Scores range from 10 to 50 with higher scores representing positive affect

  14. Positive and Negative Affect Schedule (PANAS-SF) [8 weeks]

    Survey assessing positive and negative mood states. Scores range from 10 to 50 with higher scores representing positive affect

  15. Diurnal Cortisol Slope [4 weeks]

    4 salivary cortisol collections to assess diurnal slope

  16. Diurnal Cortisol Slope [8 weeks]

    4 salivary cortisol collections to assess diurnal slope

  17. Salivary Sex Hormone Levels [4 weeks]

    1 salivary collection to assess estradiol, progesterone, testosterone, DHEAS

  18. Salivary Sex Hormone Levels [8 weeks]

    1 salivary collection to assess estradiol, progesterone, testosterone, DHEAS

Eligibility Criteria

Criteria

Ages Eligible for Study:
15 Years to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Subjects 15 years of age until 45 years of age.

  • The presence of mild to moderate acne based on investigator global assessment.

Exclusion Criteria:
  • The presence of severe acne as noted by the investigator global assessment.

  • Those with a nut allergy.

  • Those who are unwilling to discontinue oral probiotic-based supplementation to meet the washout criteria prior to enrolling.

  • Those who are unwilling to discontinue topical antibiotics and topical benzoyl peroxide to meet the washout criteria prior to enrolling.

  • Individuals who are unwilling to discontinue vitamin E containing supplements during the washout and intervention.

  • Individuals who have been on an oral antibiotic for acne within the previous 1 month.

  • Individuals who are pregnant or breastfeeding.

  • Individuals who have changed any of their hormonal based contraception within 3 months prior to joining the study.

  • Oral supplementation that has nuts in it.

  • Use of isotretinoin within the three months prior to joining the study.

  • Current tobacco smoker or a tobacco smoking history of greater than 10 pack-years.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Integrative Skin Science and Research Sacramento California United States 95819

Sponsors and Collaborators

  • Integrative Skin Science and Research
  • Codex Beauty Corporation

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Raja Sivamani, MD MS AP, Principal Investigator, Integrative Skin Science and Research
ClinicalTrials.gov Identifier:
NCT05271487
Other Study ID Numbers:
  • CB_Acne_01
First Posted:
Mar 9, 2022
Last Update Posted:
Mar 9, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Raja Sivamani, MD MS AP, Principal Investigator, Integrative Skin Science and Research
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 9, 2022